



18 January 2018

SAMED COMMENTS ON:

***Discussion paper: the need for and impact of selected interventions to
address regulatory gaps within healthcare financing, with the aim of
strengthening competition.***

SAMED is in support of some of the considerations suggested by this report, which include the introduction of the REF (or as referred to in the NHI White paper as Financial Risk Pooling) and the much needed discussions around anti-selection and the possible standardisation of benefits options in the interest of the consumer. Should discussion at the seminar include benefit design (service benefits as referred to in the NHI White paper), discussion other than anti-selection, REF and benefit options and any other discussions around PMBs, SAMED wish to highlight the need to ensure that any mechanisms introduced or amended allow for regular introduction of innovative technologies, that review / evaluation / health technology assessment of such innovative technologies is efficient and transparent. That PMBs are reviewed on a regular basis as required by legislation and allow for introduction of new innovative technologies at any point. That greater focus in terms of benefit design be afforded to preventative healthcare / treatment modalities and screening / diagnostic interventions.

SAMED, as stakeholder, has indicated that it would therefore like to attend the Seminar at the Office of the HMI on 01 February 2018.

Yours Sincerely

Tanya Vogt

SAMED Executive Officer

Not signed due to electronic circulation